Wendy Stock to Tumor Lysis Syndrome
This is a "connection" page, showing publications Wendy Stock has written about Tumor Lysis Syndrome.
Connection Strength
0.039
-
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456.
Score: 0.039
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.